Synlogic reports Q2 2023 net loss of $15.0M; Phase 3 PKU trial initiated

SYNLOGIC, INC.

2023-Q2 EPS reported -$0.44 revenue$209,000

Net loss $15.0M ($0.21/sh) vs $15.8M ($0.22/sh) in Q2 2022; cash $46.3M.
Revenue $35K from Roche collaboration, down from $152K year-over-year.
R&D expenses $11.8M; G&A $3.9M, both slightly lower than prior year.
Initiated pivotal Phase 3 Synpheny-3 trial for labafenogene marselecobac (SYNB1934) in PKU (n=150).
FDA granted Fast Track designation; WHO approved INN 'labafenogene marselecobac'.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SYNLOGIC, INC. reported the quarter ended June 30, 2023 results: revenue $35 thousand, net income consolidated net loss of $15.0 million, or $0.21 per share.

Period: the quarter ended June 30, 2023
Revenue: $35 thousand
Net income: consolidated net loss of $15.0 million, or $0.21 per share
Result: reported results

Exact text from the filing

2023 Financial Results and Financial Outlook As of June 30, 2023, Synlogic had cash and cash equivalents of $46.3 million. Revenue for the three months ended June 30, 2023 was $35 thousand compared to $152 thousand for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research collaboration with Roche for the

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

SYNLOGIC, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-040929

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.